Established in 2012, CANbridge is a  leading China-based, global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies.

We are led by a seasoned management team with significant industry experience in rare diseases, spanning R&D, clinical development, regulatory affairs, business development and commercialization, supported by a pool of talent of 151 employees where 22 had a Ph.D. and/or M.D. degree and more than 80% of our employees had experience working at multinational biopharmaceutical companies as of June 21, 2021. Our management team collectively has a track record of successfully commercializing rare disease therapies across the key markets including China, the United States, Europe, Latin America, and Southeast Asia. Leveraging our management’s expertise, we play an active role in advancing the rare disease industry and shaping the rare disease ecosystem in China. For example, our founder Dr. Xue is currently serving as the Deputy Director General of China’s Alliance for Rare Disease (CHARD).

As of June 21,2021, we had developed a comprehensive and differentiated pipeline of 13 drug assets with significant market potential targeting some of the most prevalent rare diseases as well as rare oncology indications, including three marketed products, three drug candidates at clinical stage, two at IND-enabling stage, two at preclinical stage and another three gene therapy programs at lead identification stage.

In the rare disease area, we have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Among these, we obtained the marketing approval for Hunterase®(CAN101) for MPS II in mainland China in September 2020. We are conducting a Phase 1 clinical trial in healthy volunteers for CAN106 in Singapore, and received an IND acceptance notice from the NMPA for CAN106 in April 2021 for a Phase 1 study.

In the rare oncology area, we are developing CAN008 for the treatment of glioblastoma multiforme (GBM). As of June 21,2021,we also obtained marketing approval for two other oncology products, CaphosolTM (CAN002) in mainland China and Nerlynx® (CAN030) in Greater China.

In addition to biologics and small molecules, we are investing in next-generation technology for gene therapies. We are using AAV sL65 capsid vector licensed in from LogicBio Therapeutics to develop two gene therapy products for the treatment of Fabry disease and Pompe disease, with options to develop two additional indications using the same vector and a clinical-stage gene editing program for the treatment of methylmalonic acidemia (MMA) pursuant to our collaboration agreements with LogicBio Therapeutics. We are also working with our research partner UMass on sponsored research programs to develop gene therapy solutions for neuromuscular disorders, with the exclusive option to license-in the assets for development. In addition, we are internally developing an adeno-associated virus (AAV) delivery platform targeting different tissues such as the central nervous system (CNS) and muscle.

Milestones
June 2012

CANbridge established.

July 2015

Acquires license for Apogenix's CAN008 for the treatment of glioblastoma in China

July 2016

Receives approval for CAN008 GBM Phase I/II trial in Taiwan

September 2016

Doses first patient in CAN008 GBM Phase I/II trial in Taiwan

July 2017

Submits IND application for CAN008 GBM Phase II/III trial in China

November 2017

Completes patient enrollment for CAN008 GBM Phase I trial in Taiwan

April 2018

Receives approval to commence CAN008 GBM Phase II/III trial in China

October 2018

Enters strategic partnership with WuXi Biologics for rare disease therapeutics development

July 2019

Submits NDA for CAN101 (Hunterase®) for Hunter syndrome in China

September 2019

Granted priority review for CAN101 (Hunterase®) in China

June 2020

Enters research agreement with UMass Medical School for rare disease gene therapy

September 2020

Enters into second research agreement with Umass Medical school for rare disease gene therapy

September 2020

First CANbridge rare disease treatment marketing approval in China:

Hunterase®, the first enzyme replacement therapy for Hunter syndrome in the region

April 2021

CANbridge Pharma announces strategic collaboration with LogicBio Therapeutics, securing licenses to gene delivery and editing platforms

April 2021

Mirum Pharma and CANbridge Pharma enter into exclusive licensing agreement to develop and commercialize Maralixibat in Greater China for rare liver disease

April 2021

Obtains CDE clearance from NMPA for an updated Phase II clinical first line trial application for CAN008 in China

May 2021

Completes $98 million series D and $58 million series E financing

May 2021

Begins commercialization of Hunterase® (CAN101) in mainland China

Our Team
James Xue, Ph.D.
Founder, Chairman and CEO
Glenn Hassan
Chief Financial Officer
Gerald Cox, M.D., Ph.D.
Chief Development Strategist & Interim Chief Medical Officer
Marcelo Cheresky
Chief Business Officer
Dr. Yunxiang Zhu, Ph.D
VP/Head of Global Research
Mr. Yijun Lu
General Manager of CANbridge
Minnie Ke
Vice President of Clinical Development and Medical Affairs
Jeff Lau
Vice President of Finance and Controller
Lily Liu
Head of Market Access
Stella Mao
Director, Public Affairs
Jenny Tao
Director, Quality Assurance
Rebecca Zhang
Vice President of Regulatory Affairs
Wei Zhang
Director & China Head of CMC Department
Chris Chen
Senior Director of Human Resources
Isabella Zhao, CFA
Director, Investor Relations
Tianxin Hu
Director of Clinical Operation
James Xue, Ph.D.
Founder, Chairman and CEO
Guangping Gao, Ph.D.
Advisory Board
James Xue, Ph.D.
Founder, Chairman and CEO
Mr. James Arthur Geraghty
Independent non-executive Director
Dr. Kan Chen
Non-executive Director
Dr. Derek Paul Di Rocco, Ph.D
Non-executive Director
Mr. Xiao Le
Non-executive Director
Dr. Richard James Gregory, Ph.D.
Independent non-executive Director
Mr. Peng Kuan Chan
Independent non-executive Director
Investors
Partners
Contact Us
Beijing
Beijing
Suite 301,3F,Timeloit, No. 17 RongChuang Road, Chaoyang District, Beijing, China
Tel:010 84148018
Fax:010 84148017
Shanghai
Shanghai
Suite 708, Huawen International Mansion, No.999, West Zhongshan Road, Changning District, Shanghai
Tel:021 52956319
Fax:021 52665300
Hong Kong
Hong Kong
Unit A131, 16/F, Sun Life Tower, The Gateway, Harbour City, 15 Canton Road, Tsim Sha Tsui
Taiwan
Taiwan
Room B06, 11F, No.281, Sec. 4, Xinyi Road, Da'an District, Taipei, 10681, Taiwan
Hangzhou
Hangzhou
Room 2506, Building 2, Qianjiang International Times Plaza, 111 Chengxing Road, Jianggan District, Hangzhou City, Zhejiang Province,China
Tel:0571 88210026
Fax:0571-88210207
Cambridge
Cambridge
139 Main Street, Suite 100, Cambridge, MA 02142, USA